WAVE LIFE SCIENCES LTD (WVE) — insider trading
Health Care · NASDAQ
WAVE LIFE SCIENCES LTD (WVE) has 54 reported SEC Form 4 insider transactions in our data, including 5 open-market purchases and 13 open-market sales among the most recent 54 (latest 2026-10-05).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Wagner Heidi L | Director | Grant / award / vesting (derivative) | 64,000 | — | $0 | Form 4 |
| 2026-10-05 | Wagner Heidi L | Director | Grant / award / vesting | 10,700 | — | $0 | Form 4 |
| 2026-10-05 | Verdine Gregory L. | Director | Grant / award / vesting (derivative) | 64,000 | — | $0 | Form 4 |
| 2026-10-05 | Verdine Gregory L. | Director | Grant / award / vesting | 10,700 | — | $0 | Form 4 |
| 2026-10-05 | Tan Aik Na | Director | Grant / award / vesting (derivative) | 64,000 | — | $0 | Form 4 |
| 2026-10-05 | Tan Aik Na | Director | Grant / award / vesting | 10,700 | — | $0 | Form 4 |
| 2026-10-05 | TAKANASHI KEN | Director | Grant / award / vesting (derivative) | 64,000 | — | $0 | Form 4 |
| 2026-10-05 | TAKANASHI KEN | Director | Grant / award / vesting | 10,700 | — | $0 | Form 4 |
| 2026-10-05 | Rawcliffe Adrian | Director | Grant / award / vesting (derivative) | 64,000 | — | $0 | Form 4 |
| 2026-10-05 | Rawcliffe Adrian | Director | Grant / award / vesting | 10,700 | — | $0 | Form 4 |
| 2026-10-05 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Grant / award / vesting (derivative) | 64,000 | — | $0 | Form 4 |
| 2026-10-05 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Grant / award / vesting | 10,700 | — | $0 | Form 4 |
| 2026-10-05 | HENRY CHRISTIAN O | Director | Grant / award / vesting (derivative) | 64,000 | — | $0 | Form 4 |
| 2026-10-05 | HENRY CHRISTIAN O | Director | Grant / award / vesting | 10,700 | — | $0 | Form 4 |
| 2026-10-05 | CORRIGAN MARK | Director | Grant / award / vesting (derivative) | 64,000 | — | $0 | Form 4 |
| 2026-10-05 | CORRIGAN MARK | Director | Grant / award / vesting | 10,700 | — | $0 | Form 4 |
| 2026-08-12 | Rawcliffe Adrian | Director | Open-market sale | 12,700 | $5.29 | $67.2K | Form 4 |
| 2026-08-11 | Tan Aik Na | Director | Open-market sale | 432 | $6.01 | $2.6K | Form 4 |
| 2026-08-11 | TAKANASHI KEN | Director | Open-market sale | 3,864 | $6.01 | $23.2K | Form 4 |
| 2026-08-11 | Wagner Heidi L | Director | Option exercise / conversion (derivative) | 7,000 | — | $0 | Form 4 |
| 2026-08-11 | Wagner Heidi L | Director | Open-market sale | 7,000 | $6.01 | $42.1K | Form 4 |
| 2026-08-11 | Wagner Heidi L | Director | Option exercise / conversion | 7,000 | $5.97 | $41.8K | Form 4 |
| 2026-03-30 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market purchase | 971,091 | $6.50 | $6.31M | Form 4 |
| 2026-03-27 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market purchase | 2,495,623 | $6.43 | $16.05M | Form 4 |
| 2026-03-26 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market purchase | 351,224 | $6.38 | $2.24M | Form 4 |
| 2026-03-26 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market purchase | 4,954,558 | $6.06 | $30.02M | Form 4 |
| 2026-03-23 | TAKANASHI KEN | Director | Conversion of derivative (derivative) | 3,901,348 | — | $0 | Form 4 |
| 2026-03-23 | TAKANASHI KEN | Director | Conversion of derivative | 3,901,348 | — | $0 | Form 4 |
| 2026-02-26 | Francis Chris | Officer (See Remarks) | Option exercise / conversion (derivative) | 15,294 | — | $0 | Form 4 |
| 2026-02-26 | Francis Chris | Officer (See Remarks) | Option exercise / conversion (derivative) | 17,900 | — | $0 | Form 4 |
| 2026-02-26 | Francis Chris | Officer (See Remarks) | Open-market sale | 15,294 | $15.00 | $229.4K | Form 4 |
| 2026-02-26 | Francis Chris | Officer (See Remarks) | Option exercise / conversion | 15,294 | $4.75 | $72.6K | Form 4 |
| 2026-02-26 | Francis Chris | Officer (See Remarks) | Open-market sale | 17,900 | $15.09 | $270.2K | Form 4 |
| 2026-02-26 | Francis Chris | Officer (See Remarks) | Option exercise / conversion | 17,900 | $3.87 | $69.3K | Form 4 |
| 2026-02-09 | Vargeese Chandra | Officer (See Remarks) | Open-market sale | 3,228 | $13.45 | $43.4K | Form 4 |
| 2026-02-09 | Francis Chris | Officer (See Remarks) | Open-market sale | 1,883 | $13.45 | $25.3K | Form 4 |
| 2026-02-09 | BOLNO PAUL | Director, Officer (President and CEO) | Open-market sale | 10,480 | $13.45 | $141.0K | Form 4 |
| 2026-02-09 | Moran Kyle | Officer (Chief Financial Officer) | Open-market sale | 3,588 | $13.45 | $48.3K | Form 4 |
| 2026-02-05 | Vargeese Chandra | Officer (See Remarks) | Grant / award / vesting (derivative) | 273,750 | — | $0 | Form 4 |
| 2026-02-05 | Vargeese Chandra | Officer (See Remarks) | Grant / award / vesting | 45,625 | — | $0 | Form 4 |
| 2026-02-05 | Francis Chris | Officer (See Remarks) | Grant / award / vesting (derivative) | 232,500 | — | $0 | Form 4 |
| 2026-02-05 | Francis Chris | Officer (See Remarks) | Grant / award / vesting | 38,750 | — | $0 | Form 4 |
| 2026-02-05 | BOLNO PAUL | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 1,000,000 | — | $0 | Form 4 |
| 2026-02-05 | BOLNO PAUL | Director, Officer (President and CEO) | Grant / award / vesting | 165,000 | — | $0 | Form 4 |
| 2026-02-05 | Moran Kyle | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 273,750 | — | $0 | Form 4 |
| 2026-02-05 | Moran Kyle | Officer (Chief Financial Officer) | Grant / award / vesting | 45,625 | — | $0 | Form 4 |
| 2026-01-02 | Francis Chris | Officer (See Remarks) | Option exercise / conversion (derivative) | 9,375 | — | $0 | Form 4 |
| 2026-01-02 | Francis Chris | Officer (See Remarks) | Open-market sale | 1,295 | $16.70 | $21.6K | Form 4 |
| 2026-01-02 | Francis Chris | Officer (See Remarks) | Open-market sale | 8,080 | $15.92 | $128.6K | Form 4 |
| 2026-01-02 | Francis Chris | Officer (See Remarks) | Option exercise / conversion | 9,375 | $3.14 | $29.4K | Form 4 |
| 2025-12-11 | GSK plc | 10% owner | Open-market purchase | 1,470,000 | $19.00 | $27.93M | Form 4 |
| 2025-12-08 | Rawcliffe Adrian | Director | Option exercise / conversion (derivative) | 42,000 | — | $0 | Form 4 |
| 2025-12-08 | Rawcliffe Adrian | Director | Open-market sale | 42,000 | $15.00 | $630.0K | Form 4 |
| 2025-12-08 | Rawcliffe Adrian | Director | Option exercise / conversion | 42,000 | $5.97 | $250.7K | Form 4 |
Ask the chat about WVE's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: WAVE LIFE SCIENCES LTD (WVE).
Last updated 2026-10-05 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.